Advertisement
UK markets open in 7 hours 1 minute

  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     

  • HANG SENG

    16,385.87
    +134.03 (+0.82%)
     

  • CRUDE OIL

    82.63
    -0.10 (-0.12%)
     

  • GOLD FUTURES

    2,396.10
    -1.90 (-0.08%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • Bitcoin GBP

    51,062.11
    +1,796.47 (+3.65%)
     

  • CMC Crypto 200

    1,310.95
    +425.41 (+48.04%)
     

  • NASDAQ Composite

    15,601.50
    -81.87 (-0.52%)
     

  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

Nexstim Plc’s Financial Information in 2021

Nexstim Oyj
·2-min read

Company announcement, Helsinki, 21 December 2020 at 15.15 (EET)

Nexstim Plc’s Financial Information in 2021

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it will publish the following financial information in 2021:

The 2020 Financial Statements Release and Half-Yearly Report July−December 2020 (H2) on Friday, February 26, 2021. Half-Yearly Report January-June 2021 (H1) on Friday, August 13, 2021.

Nexstim’s Annual Report 2020 will be published and also available on the Company’s website on Friday, March 5, 2021.

The Annual General Meeting is tentatively scheduled to be held on Thursday, April 29, 2021 at 10:00 am.

ADVERTISEMENT

NEXSTIM PLC

Mikko Karvinen, CEO


Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

Erik Penser Bank AB (Certified Adviser)
+46 8 463 83 00
certifiedadviser@penser.se

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit www.nexstim.com

Attachment